CD274 and cancer: Different from the repeated administrations of a large amount of manufactured PD-1 or PD-L1 antibodies into cancer patients at a 2–3-week interval, this novel PD-L1 vaccination strategy provides a novel strategy to persistently produce anti-PD-L1 antibodies and T cell response for cancer treatment and prevention.